Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

9.75USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$9.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
241,358
52-wk High
$17.96
52-wk Low
$8.10

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.07
Market Cap(Mil.): $1,029.48
Shares Outstanding(Mil.): 105.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

Nov 08 2017

BRIEF-Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211

* Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211 Source text for Eikon: Further company coverage:

Sep 27 2017

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy

Sep 19 2017

BRIEF-Lexicon Pharma reports positive pooled continuous glucose monitoring data

* Lexicon Pharmaceuticals reports positive pooled continuous glucose monitoring data from pivotal phase 3 intandem1 and intandem2 studies of sotagliflozin

Sep 08 2017

BRIEF-Lexicon Pharmaceuticals reports data from pivotal phase 3 intandem2 study of sotagliflozin

* Lexicon Pharmaceuticals reports additional positive data from pivotal phase 3 intandem2 study of sotagliflozin

Aug 15 2017

BRIEF-Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes

* Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes

Jul 31 2017

BRIEF-Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo

* Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo® (telotristat ethyl) Source text for Eikon: Further company coverage:

Jul 21 2017

BRIEF-Lexicon Pharmaceuticals amends collaboration and license agreement

* Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH

Jul 07 2017

BRIEF-Lexicon Pharmaceuticals says Xermelo 250 mg has been included as a recommended treatment option in latest national comprehensive cancer network

* Lexicon Pharmaceuticals Inc - Xermelo 250 mg has been included as a recommended treatment option in latest national comprehensive cancer network

Jun 19 2017

BRIEF-Lexicon Pharmac reports positive late-stage data on diabetes drug

* Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes

Jun 09 2017

Competitors

Earnings vs. Estimates